About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Mantle Cell Lymphoma >  Mantle Cell Lymphoma abstracts - ASH 2012

Last update: 11/07/2012

 

Comments or Questions?

96 abstracts

Mantle Cell Clinical Trials:
Untreated: http://bit.ly/hOL82j | Relapsed: http://bit.ly/ff4a55
 
  1. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)
  2. Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin
  3. Outcome and Prognostic Factors in Patients with Mantle Cell Lymphoma Relapsing After Autologous Stem Cell Transplantation: A Retrospective Study of the EBMT
  4. Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study
  5. Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma
  6. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study
  7. Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation
  8. A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis
  9. A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/ Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
  10. High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis
  11. SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment
  12. Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)
  13. Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma
  14. Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma
  15. Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma
  16. Inhibition of Histone Deacetylase 6 (HDAC6) Disrupts the Tolerogenic STAT3 Signaling Pathway and Augments Antitumor Immune Responses in Mantle Cell Lymphoma (MCL)
  17. Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study
  18. Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome
  19. Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL)
  20. Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy
  21. Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up
  22. Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM)
  23. Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition
  24. Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era
  25. Subanalysis of the StiL NHL 1-2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response
  26. Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis
  27. Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study
  28. Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial
  29. Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)
  30. The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma
  31. Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib
  32. Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma
  33. Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models
  34. Cyclin D1 (CCND1) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases
  35. Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse
  36. Microrna-16 Regulates BMI1 in the Clonogenic Side Population of Refractory Mantle Cell Lymphoma
  37. Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma
  38. Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo
  39. Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
  40. Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma
  41. Meta Analysis of Grade 3 and/or 4 Toxicities in Follicular (FL) and Mantle Cell (MCL) Non-Hodgkin Lymphoma (NHL) Patients Receiving Maintenance Rituximab (MR): Impact of Schedule, Histology, and Induction Regimen
  42. Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma
  43. 90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients
  44. Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)
  45. Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Targeting NF-κB and mTOR Signaling Pathways in Vitro and in Vivo
  46. Molecular Mechanisms of Antitumor Activity of the Selective Inhibitor of Nuclear Export (SINE) CRM1 Antagonist KPT-185 in Mantle Cell Lymphoma
  47. Autologous and Allogeneic Donor Transplantation for Mantle Cell Lymphoma in Rituximab Era: Impact of Pre-Transplant Burden On Survival
  48. Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma
  49. The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib
  50. Pilot Study of Lenalidomide-Rituximab Combination in Relapsed/Refractory Diffuse Large B Cell Lymphoma
  51. Diagnostic Value of CD200 Expression for the Differentiation Between Chronic Lymphocytic Leukemia (CLL), CLL with Increased Prolymphocytes (CLL/PL) and Mantle Cell Lymphoma
  52. SOX11 over-Expression Is a Specific Marker for Mantle Cell Lymphoma and Correlates with t(11;14) Translocation, CCND1 Expression, and an Adverse Prognosis
  53. Abexinostat (S78454 / PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients
  54. A Synthetic Lethal RNA Interference Screen Identifies Components of Genotoxic Stress Response As Targets for Anti-CCND1 Therapy in Mantle Cell Lymphoma
  55. The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study
  56. Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin’s Lymphoma Receiving Radioimmunotherapy
  57. An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin’s Lymphoma: Preliminary Safety and Efficacy Data
  58. CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis
  59. Outcomes of Eam Conditioned Autologous Haematopoietic Stem Cell Transplantation for Lymphoma. A Matched Pairs Retrospective Single Centre Study Analysis
  60. Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma
  61. A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma
  62. Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection
  63. Full Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma
  64. Primary Refractory Disease in Non-Hodgkin’s Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy
  65. MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study
  66. Nonmyeloablative Allogeneic (Allo) BMT for B-Cell Lymphoma with Posttransplant Rituximab: Donor Selection by Prioritizing FCGR3A-158 Polymorphism Over HLA Matching
  67. A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
  68. Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin’s Lymphoma Treated with Splenectomy
  69. Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings
  70. Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma
  71. Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results
  72. Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute
  73. Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma
  74. Defining the Malignant Epigenome in Non-Hodgkin Lymphoma
  75. Adverse Prognostic Impact of Vascular Endothelial Growth Factor Gene Polymorphism in Patients with Non-Hodgkin Lymphoma
  76. A Phase I Trial of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
  77. Favorable Outcome in Patients with Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine and Treosulfan As the Preparative Regimen
  78. RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years
  79. Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Mantle Cell Lymphoma and Follicular Lymphoma
  80. Positive Positron Emission Tomography (PET) Scan in Non-Hodgkin Lymphoma Pre-Transplant Had No Impact On Relapse and Survival After Allogenenic Transplantation
  81. Drug Development Targeting Microenvironment for Malignant Lymphoma
  82. Mantle Cell Lymphoma (How I treat)
  83. 731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous Transplantation for Lymphoma and other B Cell Malignancies
  84. Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center
  85. Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients
  86. Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies
  87. Clonosight: A Standardized Clinical Assay for Measurement of Minimal Residual Disease in Leukemias and Lymphomas
  88. 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
  89. 625. Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
  90. 731. Clinical Allogeneic and Autologous Transplantation - Results: Transplant for Lymphoma and Lymphoid Leukemia
  91. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the "Bolus" Infusion Schedule of Alvocidib
  92. Therapeutic Targeting of B-Cell Receptor Signaling Pathways
  93. Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies
  94. Next-Generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation
  95. 703. Adoptive Immunotherapy I
  96. 603. Oncogenes and Tumor Suppressors II

 

See also Other Ways to Help

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.